Psoriatic arthritis

Soumya M. Reddy; Clifton O. Bingham

doi:10.1007/3-540-27190-2_11

Psoriatic arthritis

Soumya M. Reddy, Clifton O. Bingham

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Until recently, psoriatic arthritis (PsA) has not received the same attention as other inflammatory arthritides with regards to the development of formal outcome measures, in part due to the difficulty of studying such a heterogeneous disease.As a result,many of the treatments, as well as outcome measures, used in the evaluation of PsA have been borrowed from the study of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Indeed, there are currently very few instruments that are diseasespecific for the evaluation of PsA. In this chapter we will review the existing indices that have been applied to PsA from other disease states and review those that have been further validated in this disease.Outcome measures specifically designed for the evaluation of PsA will also be reviewed. The need for disease-specific measures is highlighted by the development of new medications and the need for formal validated outcome measures for use in future clinical trials.

Original language	English (US)
Title of host publication	Psoriasis and Psoriatic Arthritis
Subtitle of host publication	An Integrated Approach
Publisher	Springer Berlin Heidelberg
Pages	95-107
Number of pages	13
ISBN (Print)	3540212809, 9783540212805
DOIs	https://doi.org/10.1007/3-540-27190-2_11
State	Published - Dec 1 2005

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/3-540-27190-2_11

Cite this

@inbook{9d0a0aea5eb246ccbf243a23cded31c6,

title = "Psoriatic arthritis",

abstract = "Until recently, psoriatic arthritis (PsA) has not received the same attention as other inflammatory arthritides with regards to the development of formal outcome measures, in part due to the difficulty of studying such a heterogeneous disease.As a result,many of the treatments, as well as outcome measures, used in the evaluation of PsA have been borrowed from the study of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Indeed, there are currently very few instruments that are diseasespecific for the evaluation of PsA. In this chapter we will review the existing indices that have been applied to PsA from other disease states and review those that have been further validated in this disease.Outcome measures specifically designed for the evaluation of PsA will also be reviewed. The need for disease-specific measures is highlighted by the development of new medications and the need for formal validated outcome measures for use in future clinical trials.",

author = "Reddy, {Soumya M.} and Bingham, {Clifton O.}",

year = "2005",

month = dec,

day = "1",

doi = "10.1007/3-540-27190-2_11",

language = "English (US)",

isbn = "3540212809",

pages = "95--107",

booktitle = "Psoriasis and Psoriatic Arthritis",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Psoriatic arthritis

AU - Reddy, Soumya M.

AU - Bingham, Clifton O.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Until recently, psoriatic arthritis (PsA) has not received the same attention as other inflammatory arthritides with regards to the development of formal outcome measures, in part due to the difficulty of studying such a heterogeneous disease.As a result,many of the treatments, as well as outcome measures, used in the evaluation of PsA have been borrowed from the study of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Indeed, there are currently very few instruments that are diseasespecific for the evaluation of PsA. In this chapter we will review the existing indices that have been applied to PsA from other disease states and review those that have been further validated in this disease.Outcome measures specifically designed for the evaluation of PsA will also be reviewed. The need for disease-specific measures is highlighted by the development of new medications and the need for formal validated outcome measures for use in future clinical trials.

AB - Until recently, psoriatic arthritis (PsA) has not received the same attention as other inflammatory arthritides with regards to the development of formal outcome measures, in part due to the difficulty of studying such a heterogeneous disease.As a result,many of the treatments, as well as outcome measures, used in the evaluation of PsA have been borrowed from the study of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Indeed, there are currently very few instruments that are diseasespecific for the evaluation of PsA. In this chapter we will review the existing indices that have been applied to PsA from other disease states and review those that have been further validated in this disease.Outcome measures specifically designed for the evaluation of PsA will also be reviewed. The need for disease-specific measures is highlighted by the development of new medications and the need for formal validated outcome measures for use in future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84889982370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889982370&partnerID=8YFLogxK

U2 - 10.1007/3-540-27190-2_11

DO - 10.1007/3-540-27190-2_11

M3 - Chapter

AN - SCOPUS:84889982370

SN - 3540212809

SN - 9783540212805

SP - 95

EP - 107

BT - Psoriasis and Psoriatic Arthritis

PB - Springer Berlin Heidelberg

ER -

Psoriatic arthritis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this